Drug intelligence / Profile preview

UC-NK101

Development stage: Preclinical
Lead developer: Universal Cells
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UC-NK101 is a preclinical iPSC-derived Natural Killer (NK) cell therapy. It was part of Universal Cells' portfolio, a company acquired by Astellas Pharma in April 2022. Astellas's acquisition aimed to expand into the allogeneic cell therapy space, particularly for oncology. This therapy leverages induced pluripotent stem cells to generate NK cells, which are a type of immune cell known for their ability to recognize and kill cancer cells.

Beyond the preview

Go deeper on UC-NK101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UC-NK101.

Explore the full profile